PMDA — authorised 20 September 2013
- Marketing authorisation holder: JANSSEN PHARMACEUTICAL K.K.
- Status: approved
PMDA authorised Invega Sustenna on 20 September 2013
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 20 September 2013.
JANSSEN PHARMACEUTICAL K.K. holds the Japanese marketing authorisation.